Clinical Trials
3
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Phase 1
- Conditions
- Thoracic Solid Malignant Tumor
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Stella Pharma Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT06603987
- Locations
- 🇯🇵
ORIX Kouraibashi Bldg. 8F 3-2-7 Kouraibashi Chuo-ku, Osaka, Japan
A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA
Phase 2
Active, not recruiting
- Conditions
- Unresectable Angiosarcoma
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Stella Pharma Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT05601232
- Locations
- 🇯🇵
National Cancer Center Hospital, Tokyo, Japan
News
National Cancer Center to Initiate Basket Trial of BNCT for Thoracic Malignancies
The National Cancer Center Japan will conduct a Phase I/II basket trial of Boron Neutron Capture Therapy (BNCT) for unresectable and recurrent thoracic malignant solid tumors.